Table 3.
Ongoing clinical trials evaluating CAR T-cell treatment in CLL patients.
| NCT number | Drug regimen | Setting |
|---|---|---|
| NCT03881774 | Cord blood derived CAR T cells | R/R CLL after autologous CAR T cells therapy or who fail to preparation for autologous CAR T cells |
| NCT04271410 | Anti-CD19 CAR T cells | R/R CLL |
| NCT04156243 | Anti-CD19 CAR T cells | R/R CLL |
| NCT04014894 | Anti-CD19 CAR T cells | R/R CLL |
| NCT04271800 | Anti-CD19 CAR T cells | R/R CLL |
| NCT03685786 | Anti-CD19 CAR T cells + autologous HSCT | MRD+ CLL |
| NCT03960840 | Autologous anti-CD19 CAR T cells | SD or PR CLL after 6-month therapy with ibrutinib or R/R CLL |
| NCT02963038 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03110640 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03302403 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03579888 | Autologous anti-CD19 CAR T cells | R/R CLL who have undergone allogeneic HSCT |
| NCT02153580 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03050190 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03624036 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03853616 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03383952 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03191773 | Autologous anti-CD19 CAR T cells | R/R CLL |
| NCT03166878 | Allogeneic anti-CD19 CAR T cells | R/R CLL |
| NCT03277729 | Autologous anti-CD20 CAR T cells | R/R CLL |
| NCT00621452 | Autologous anti-CD20 CAR T cells | R/R CLL |
| NCT00012207 | Autologous anti-CD20 CAR T cells | R/R CLL |
| NCT01735604 | Autologous anti-CD20 CAR T cells | R/R CLL |
| NCT04030195 | Allogeneic anti-CD20 CAR T cells | R/R CLL |
| NCT02794961 | Autologous anti-CD22 CAR T cells | R/R CLL |
| NCT02194374 | Autologous anti-ROR1 CAR T cells | R/R or untreated CLL with del17p and not eligible for allogeneic HSCT |
| NCT02706392 | Autologous anti-ROR1 CAR T cells | R/R CLL |
| NCT04156178 | Anti-CD19/CD20 CAR T cells | R/R CLL |
| NCT04260945 | Anti-CD19/CD20 CAR T cells | R/R CLL |
| NCT04007029 | Autologous anti-CD19/CD20 CAR T cells | R/R CLL |
| NCT03097770 | Autologous or allogenic anti-CD19/CD20 CAR T cells | R/R CLL |
| NCT03398967 | Allogeneic anti-CD19/CD20 or anti-CD19/CD22 CAR T cells | R/R CLL |
| NCT04029038 | Autologous anti-CD19/CD22 CAR T cells | R/R CLL |
| NCT03185494 | Autologous or allogenic anti-CD19/CD22 CAR T cells | R/R CLL |
| NCT03125577 | Autologous anti-CD19 and anti-CD20/CD22/CD30/CD38/CD70/CD123 CAR T cells | R/R CLL |
CLL, chronic lymphocytic leukemia; HSCT, hematopoietic stem cell transplantation, MRD, minimal residual disease; PR partial response; R/R relapsed or refractory; SD, stable disease.